Enhancement of the antitumor effect of HER2‐directed CAR‐T cells through blocking epithelial‐mesenchymal transition in tumor cells

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager

(2018) Anna Wing et al.   Cancer Immunology Research

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy

(2018) Chunyan Yue et al.   OncoImmunology

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

(2018) Armin Ghobadi   Current Research in Translational Medicine

Identification of the tumour transition states occurring during EMT

(2018) Ievgenia Pastushenko et al.   NATURE

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

(2018) Marion Alcantara et al.   LEUKEMIA

CD19, from bench to bedside

(2017) Xinchen Li et al.   IMMUNOLOGY LETTERS

FDA Approval of Tisagenlecleucel

(2017) Peter B. Bach et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

EMT: Present and future in clinical oncology

(2017) Patricia G. Santamaria et al.   Molecular Oncology

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

(2017) Biliang Hu et al.   Cell Reports

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

(2017) Brian Hutzen et al.   Molecular Therapy-Oncolytics

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

(2016) C. H. J. Lamers et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

TGF-β Tumor Suppression through a Lethal EMT

(2016) Charles J. David et al.   CELL

Anti-BCMA CAR T cells show promise in MM

(2016) Peter Sidaway   Nature Reviews Clinical Oncology

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

(2016) Gregory L. Beatty et al.   PHARMACOLOGY & THERAPEUTICS

Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects

(2016) Shengmeng Di et al.   Science China-Life Sciences

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

CD19 chimeric antigen receptor T cell therapy for haematological malignancies

(2015) Sara Ghorashian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

(2015) Hinrich Abken   Immunotherapy

Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression

(2015) Xin Ye et al.   TRENDS IN CELL BIOLOGY

LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer

(2015) Sheng-Jia Shi et al.   Oncotarget

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance

(2014) Yulong Shang et al.   CURRENT CANCER DRUG TARGETS

TGFβ in T cell biology and tumor immunity: Angel or devil?

(2014) Eric Tu et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The network of epithelial–mesenchymal transition: potential new targets for tumor resistance

(2014) Danupon Nantajit et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells

(2014) Keisuke Watanabe et al.   JOURNAL OF IMMUNOLOGY

The Upregulation of Immune Checkpoint Ligand PD-L1 in Tumour Microenvironment

(2014) W. Xu et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment

(2014) Gregory L Beatty et al.   OncoImmunology

Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells

(2014) Katherine Woods et al.   Frontiers in Oncology

Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis

(2013) I. Akalay et al.   CANCER RESEARCH

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

(2013) Sunitha Kakarla et al.   MOLECULAR THERAPY

Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: Potential role of hypoxia

(2012) Delphine Tamara Marie-Egyptienne et al.   CANCER LETTERS

TGF-β signaling and epithelial–mesenchymal transition in cancer progression

(2012) Yoko Katsuno et al.   CURRENT OPINION IN ONCOLOGY

The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer

(2011) Shogo Yamamura et al.   INTERNATIONAL JOURNAL OF CANCER

The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system

(2010) Eliza Wiercinska et al.   BREAST CANCER RESEARCH AND TREATMENT

Transforming growth factor-β enhances matrix metalloproteinase-2 expression and activity through AKT in fibroblasts derived from angiofibromas in patients with tuberous sclerosis complex

(2010) C.-H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

EMT, the cytoskeleton, and cancer cell invasion

(2009) Mahmut Yilmaz et al.   CANCER AND METASTASIS REVIEWS